Jul/10
29
Merck grants license to LabCorp for development of genetic test to predict response of HCV patients
0 Comments | Posted by admin in Gene therapy
Merck announced a non-exclusive license agreement with Laboratory Corporation of America Holdings (LabCorp) for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus (HCV) infection to peginterferon alpha-based therapy.
